Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. The company is headquartered in Suzhou, Jiangsu and currently employs 605 full-time employees. The company went IPO on 2019-10-28. The firm's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The firm's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The firm primarily conducts its businesses in domestic market.
06855.HK stock price ended at $52.15 on 金曜日, after dropping 2.34%
On the latest trading day Jan 16, 2026, the stock price of 06855.HK fell by 2.34%, dropping from $53.65 to $52.15. During the session, the stock saw a volatility of 4.34%, with prices oscillating between a daily low of $51.85 and a high of $54.10. On the latest trading day, the trading volume for 06855.HK decreased by 148.2K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 1.9M shares were traded, with a market value of approximately $19.3B.